Perspective Therapeutics, Inc. (NYSE:CATX) Position Raised by Nicholson Wealth Management Group LLC

Nicholson Wealth Management Group LLC increased its stake in shares of Perspective Therapeutics, Inc. (NYSE:CATX) by 0.4% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 1,609,283 shares of the company’s stock after buying an additional 7,000 shares during the quarter. Perspective Therapeutics comprises approximately 3.4% of Nicholson Wealth Management Group LLC’s investment portfolio, making the stock its 2nd biggest holding. Nicholson Wealth Management Group LLC owned 2.38% of Perspective Therapeutics worth $5,134,000 at the end of the most recent reporting period.

Other large investors have also recently made changes to their positions in the company. FMR LLC boosted its holdings in Perspective Therapeutics by 3,994.9% in the third quarter. FMR LLC now owns 5,504,822 shares of the company’s stock valued at $73,489,000 after purchasing an additional 5,370,392 shares during the last quarter. State Street Corp boosted its holdings in Perspective Therapeutics by 119.6% in the third quarter. State Street Corp now owns 2,190,239 shares of the company’s stock valued at $29,240,000 after purchasing an additional 1,192,812 shares during the last quarter. Hills Bank & Trust Co purchased a new stake in Perspective Therapeutics in the third quarter valued at $13,722,000. Janus Henderson Group PLC boosted its holdings in Perspective Therapeutics by 8.0% in the third quarter. Janus Henderson Group PLC now owns 4,799,352 shares of the company’s stock valued at $64,014,000 after purchasing an additional 355,685 shares during the last quarter. Finally, WealthPlan Investment Management LLC purchased a new stake in Perspective Therapeutics in the third quarter valued at $4,530,000. 54.66% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling

In related news, Director Heidi Henson acquired 25,975 shares of the stock in a transaction that occurred on Wednesday, December 4th. The stock was purchased at an average price of $3.85 per share, with a total value of $100,003.75. Following the transaction, the director now owns 25,975 shares of the company’s stock, valued at approximately $100,003.75. This trade represents a ∞ increase in their position. The acquisition was disclosed in a filing with the SEC, which is available at the SEC website. Also, CEO Johan M. Spoor purchased 14,500 shares of the firm’s stock in a transaction on Monday, November 25th. The stock was acquired at an average cost of $3.78 per share, with a total value of $54,810.00. Following the transaction, the chief executive officer now directly owns 152,072 shares in the company, valued at $574,832.16. This trade represents a 10.54 % increase in their ownership of the stock. The disclosure for this purchase can be found here. In the last quarter, insiders purchased 67,570 shares of company stock valued at $256,789. Company insiders own 3.52% of the company’s stock.

Analyst Ratings Changes

Several research firms have commented on CATX. UBS Group began coverage on shares of Perspective Therapeutics in a report on Thursday, October 24th. They issued a “buy” rating and a $20.00 price target on the stock. Bank of America downgraded shares of Perspective Therapeutics from a “buy” rating to a “neutral” rating and decreased their price objective for the stock from $24.00 to $5.00 in a research report on Monday, November 25th. Wedbush reiterated an “outperform” rating and issued a $11.00 price objective on shares of Perspective Therapeutics in a research report on Friday, January 24th. Oppenheimer decreased their price objective on shares of Perspective Therapeutics from $22.00 to $16.00 and set an “outperform” rating for the company in a research report on Friday, November 22nd. Finally, Royal Bank of Canada restated an “outperform” rating and set a $16.00 price target on shares of Perspective Therapeutics in a research report on Tuesday, January 14th. One investment analyst has rated the stock with a hold rating, seven have assigned a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Buy” and a consensus target price of $15.14.

Perspective Therapeutics Price Performance

Perspective Therapeutics stock opened at $2.84 on Friday. The firm has a 50 day simple moving average of $3.32 and a 200-day simple moving average of $8.53. Perspective Therapeutics, Inc. has a 1-year low of $2.70 and a 1-year high of $19.05.

About Perspective Therapeutics

Perspective Therapeutics, Inc, together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma.